| Trial ID # | NCT04152499 |
| Phase | I/II |
| Drug Class | Antibody Drug Conjugates: TROP2 |
| Drug Name | Sacituzumab tirumotecan |
| Alternate Drug Names | sac-TMT, MK-2870, SKB264 |
| Drugs in Trial | Sacituzumab tirumotecan |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 35, at least 2 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, evaluated per RECIST |
| Efficacy | ORR: 37.1% (13PR) |
| Clinically Significant Adverse Events | Serious AE: overall (37.5%) |
| Conclusion | Sacituzumab tirumotecan (Sac-TMT) monotherapy shows promising anti-tumor activity with a manageable safety profile in patients with platinum resistant or refractory ovarian cancer |
| Reference | Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. Ann Oncol (2024) 35 (2) abstract 715MO Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. Ann Oncol (2024) 35 (2) abstract 715MO |